BACKGROUND: Concomitant quantification of multiple mutant KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) alleles may provide information in addition to that provided by standard mutationdetection procedures. We assessed the feasibility of a nanofluidic digital PCR array platform to detect and quantify KRAS mutations simultaneously in clinically relevant samples.
Mutations in the KRAS
8 (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene, which are located primarily in codons 12 and 13 of exon 2 (1 ) , are among the most frequently detected activating mutations in human cancers. Up to 65% to 100% of pancreatic tumors harbor codon 12 and 13 mutations, whereas this proportion decreases to 30%-50% in colorectal tumors. In pancreatic and colorectal human cancers, KRAS mutations appear in the early stages of tumorigenesis (2) (3) (4) .
Somatic mutations can serve as biomarkers that allow tumor cells to be distinguished from their normal counterparts. Mutations within tumor cells and in DNA released by tumor cells into clinical samplessuch as blood, lymph, stool, or urine-can be used to detect cancers (5 ) . The use of KRAS mutations for the early detection of pancreatic and colorectal tumors has been explored with fine-needle aspirates, pancreatic juice, or stool DNA, either alone or in combination with other genetic and epigenetic markers (6 -8 ) . The usefulness of the detection of KRAS mutations as a prognostic marker has also been explored, but the results have been inconclusive. With the advent of ther-apies that target the epidermal growth factor receptor in patients with metastatic colorectal cancer, KRAS has emerged as a major predictive marker, because tumors containing KRAS mutations are believed to be unresponsive to cetuximab or panitumumab treatment (9 -14 ) . Detection of KRAS mutations has also been clinically useful for diagnosing pancreatic tumors via analysis of tumor biopsies, pancreatic juice, serum, and stool DNA (6, 15, 16 ) . In this setting, the lack of diagnostic specificity has precluded more-widespread use.
To use tumor-specific somatic mutations as biomarkers for clinical oncology requires that they be detected even when they present in only a small proportion of cells within the tumor or when the mutations occur in a large excess of nonmutated DNA. An increasing number of techniques are being developed to detect KRAS mutations, and these techniques have different levels of analytical sensitivity and specificity. Direct sequencing is capable of detecting a mutant allele at a prevalence of Յ20% (16, 17 ) . Such frequently used techniques as pyrosequencing and allele-specific PCR have analytical sensitivities ranging from 1% to 10% for the detection of mutant DNA diluted into a background of wild-type DNA (18 -20 ) . The TheraScreen K-RAS Mutation Kit (DxS Limited), a test based on an amplification-refractory mutation system (ARMS) 9 technology and possibly the most widely used CEmarked kit for diagnostic use, has a reported analytical sensitivity of approximately 1% of mutant allele (21 ) . More-sensitive methods are available for KRAS analysis, such as mutant-enriched PCR (9 ) and COLD-PCR, which has a reported analytical sensitivity of about 0.1% (22) (23) (24) or better (25 ) .
Digital PCR is an alternative when considering highly sensitive techniques. Whereas conventional digital PCR uses sequential limiting dilutions of target DNA followed by PCR amplification (26, 27 ) to perform single-molecule PCR, the digital array performs the same function by partitioning DNA molecules before the PCR. The use of multiple independent chambers facilitates the detection of rare copies of a mutated allele in a limited amount of patient sample. The digital array has previously been used for a variety of different applications, including absolute quantification (26 ), mutation detection (28, 29 ) , and studies of variation in copy number (30, 31 ) .
We previously hypothesized that the variation profiles of pathologic alleles that are eventually expanded in tumors are due to the interaction between genetic instability and selection (32, 33 ) . The analysis of profiles of mutation frequencies for appropriate loci selected according to the tumor type reflects the dynamics of carcinogenesis and yields a novel type of biomarker. This novel metric, "mutational load distribution analysis," is based on precise quantification of a subset of KRAS and TP53 (tumor protein 53) alleles and can effectively discriminate between normal pancreatic tissue and pancreatic tumors (34 ) . This type of measure requires quantitative technologies capable of directly measuring the number of DNA molecules tested per assay. Recent developments have made digital PCR a feasible methodology amenable for the analysis of routine samples.
In this study, we assessed the feasibility of the nanofluidic digital PCR array (Fluidigm) platform as a quantitative and analytically sensitive approach to detect KRAS mutations in routinely obtained samples. We preliminarily explored the usefulness of quantifying multiple KRAS alleles simultaneously in colorectal and pancreatic carcinoma samples.
Materials and Methods

PATIENTS AND SAMPLES
All patients gave informed written consent to participate and to have their biological specimens analyzed. The study was cleared by the Ethical Committee of the University Hospital of Bellvitge and the Hospital of Terrassa.
We assessed 2 groups of patients (colorectal disease and pancreatic disease). The colorectal disease group included biopsies from 14 patients with sporadic adenomas, 27 patients with sporadic carcinomas, and 5 patients with a normal colonoscopy result (controls). Fresh frozen tumors or normal biopsy samples were obtained from surgical resections (partial or complete colectomy) or from endoscopy examinations carried out between 2007 and 2010 at the University Hospital of Bellvitge and the Hospital of Terrassa. In a small subset of these tumors, corresponding formalin-fixed, paraffin-embedded blocks were analyzed. The pancreatic disease group included 42 patients with carcinoma of the exocrine pancreas, 4 patients with adenocarcinomas of the ampulla of Vater, and 6 patients with chronic pancreatitis. Retrograde pancreatic juice samples were obtained from all of these patients during surgery. The corresponding biopsy sample of the tumor was also analyzed for a small set of these patients (n ϭ 10). All biological samples were immediately stored at Ϫ80°C until use.
The main clinicopathologic characteristics of the patients are summarized in Table 1 . Examination of sections stained with hematoxylin and eosin verified the pathologic diagnosis, and carcinomas were classi-fied according to the Union for International Cancer Control (UICC) TNM classification system.
DNA EXTRACTION
DNA from fresh frozen tissues was extracted with the saline method (35 ) . DNA from cell lines with known KRAS mutations (MIA PaCa-2, SW480, NP9, SW1116, A549, and CAL-62) was extracted with the FlexiGene DNA Kit (Qiagen). DNA was extracted from pancreatic juice with the phenol-chloroform method (33, 36 ) . DNA was extracted from formalin-fixed, paraffin-embedded tissues with the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions. DNA quality and concentration were measured with a NanoDrop 1000 spectrophotometer (Thermo Scientific).
NANOFLUIDIC DIGITAL PCR
Digital PCR was performed with the Digital Array (Fluidigm Europe), a nanofluidic digital array that partitions a sample premixed with PCR reagents into hundreds of individual PCR reactions, thus allowing the absolute quantification of target sequences. The KRAS mutation analysis is based on allele-specific PCR. We designed external primers for complementary probe regions and TaqMan MGB probes (Applied Biosystems/Life Technologies) to screen for the 6 common mutations in KRAS codon 12 (see Table 1 
The digital array underwent thermocycling on the BioMark™ Real-Time PCR System (Fluidigm Europe). The thermocycling conditions were: 120 s at 50°C, a hot start at 95°C for 10 min, and 40 cycles of 15 s of denaturation at 95°C and 1 min of annealing and extension at 60°C. The FAM and VIC signals of all chambers were recorded at the beginning of each annealing step. BioMark Digital PCR Analysis Software was used to process the data, analyze PCR amplification, and count the numbers of VIC-positive chambers and FAM-positive (i.e., KRAS mutant positive) chambers in each panel. We used 6-carboxy-X-rhodamine (ROX) signals as an internal positive PCR control. Software was used to calculate the number of positives in each panel and to generate data as heat maps with corresponding amplification curves for each of the 770 chambers. The Fluidigm digital PCR analysis software uses a Poisson model to estimate the number of DNA molecules from the count of positive wells (estimated targets) for each allele, because positivity for a well may correspond to multiple DNA molecules. Mutant allele frequencies for a given case were calculated as the number of estimated targets for a given probe divided by the total number of alleles analyzed. The total number of alleles analyzed was the sum of the median of wild-type estimated targets after probing for each mutation and the total number of estimated mutant alleles in the sample.
CONVENTIONAL REAL-TIME PCR ANALYSIS
We used a real-time PCR machine (LightCycler 480; Roche Applied Science) to perform real-time assays with the same set of primers and probes. We added 20 ng genomic DNA to 2.5 L TaqMan Universal PCR Master Mix (Applied Biosystems), 0.125 L of the 40ϫ probe mixture, and 1.375 L water. The thermocycling parameters were the same for all of the alleles tested: 95°C for 10 min and 40 cycles at 92°C for 15 s and an annealing temperature of 60°C for 1 min. A final step of allelic discrimination is necessary to differentiate between the VIC and FAM signals. The LightCycler 480 Software (version 1.5) determines the genotype of the sample by measuring the intensity distribution of dyes used after the PCR.
Results
ANALYTICAL SENSITIVITY OF THE DIGITAL PCR
To determine the analytical sensitivity of the 2 techniques (nanofluidic digital PCR and conventional realtime PCR), we performed a reconstitution experiment with all of the known KRAS mutations at codon 12 (Gly12Cys, Gly12Val, Gly12Asp, Gly12Ala, Gly12Ser, and Gly12Arg; see Table 1 in the online Data Supplement). Serial reconstitutions (25%, 10%, 5%, 1%, 0.5%, 0.1%, and 0.05%) of mutant DNA (MIA PaCa-2, SW480, NP9, SW1116, A549, and CAL-62, respectively) were prepared with increasing amounts of wildtype DNA. Nanofluidic digital PCR was capable of detecting mutant alleles at a relative concentration of 0.05% to 0.1%, depending on the variant analyzed ( Fig.  1 ; see Figs. 1-3 in the online Data Supplement). The analytical sensitivity of the conventional real-time PCR analysis was Ն1% mutant in a background of wild-type DNA (see Fig. 4 in the online Data Supplement).
Cross-detection of distinct KRAS mutant alleles was analyzed. Mixtures containing a high proportion (25% and 10%) of the 2 most frequent mutations (Gly12Asp and Gly12Val) and 1% of the minor mutations were hybridized to Ser, Arg, Cys, and Ala probes ( Table 2; 
COLORECTAL DISEASES
Neither digital PCR nor conventional allele-specific PCR detected mutations in the control samples. Nine (64%) of the 14 patients with adenomas were positive for KRAS mutants by conventional PCR, whereas digital PCR was able to increase this number to 11 (79%). Two synchronic adenomas scored positive for KRAS mutants with both techniques. Sixteen (59%) of 27 patients with carcinomas were determined to have a KRAS mutant by conventional PCR. Two additional cases were detected with digital PCR (Table 3 ; see Fig. 6 in the online Data Supplement). In all, 4 cases were reclassified as positive when digital PCR was used.
The quantification of KRAS mutations with the nanofluidic digital PCR array is shown in Fig. 2 (also see Fig. 7 in the online Data Supplement). The mean KRAS mutational load-the sum of mutated allele frequencies for a given case-was 20.1% for the adenoma cases and was increased to 21.5% in the carcinoma cases (see Fig. 8 in the online Data Supplement). All KRAS mutant-positive adenomas and 16 of 18 carcinomas harbored a dominant allele. In contrast, the proportion of adenoma cases having multiple mutant alleles was 21% (3 of 14) for adenomas and 7% (2 of 27) for the carcinomas ( Fig. 2; see Fig. 7 in the online Data Supplement).
PANCREATIC DISEASES
Conventional allele-specific PCR revealed the presence of one or more KRAS mutant alleles in 26 (62%) of 42 samples of pancreatic juice from carcinoma cases. Digital PCR increased the number of positive cases to 34 (81%) ( Table 3 ; see Fig. 6 in the online Data Supplement). Additionally, digital PCR was capable of depicting heterogeneity within the KRAS locus in 25 cases, whereas conventional PCR detected multiple KRAS alleles in only 12 cases. A dominant allele was present in 16 of the carcinomas of the exocrine pancreas ( Fig. 2; see Fig. 7 in the online Data Supplement). A small subset of carcinomas of the ampulla was analyzed. Two of these carcinomas were positive with conventional PCR, and digital PCR detected an additional KRAS mutant-positive carcinoma. Of the 6 patients with chronic pancreatitis (all of whom underwent operations), conventional real-time PCR revealed the presence of KRAS mutations in 2 cases, and digital PCR also identified 2 cases as positive. Only 1 case (P1) was detected with both techniques, and this case was eventually diagnosed as a pancreatic adenocarcinoma (see Fig.  7B in the online Data Supplement). The mean KRAS mutational loads in the pancreatic juice samples from the exocrine pancreatic carcinoma cases and the ampullary carcinoma cases were similar (12.7% and 9.4%, respectively; see Fig. 8 in the online Data Supplement). In contrast, the KRAS mutational load in chronic pancreatitis was 6.1%. Given that pancreatic juice does not sample only the tumor, we assessed the correlation between juice and tumor biopsies in 10 cases (5 with single mutations in pancreatic juice samples and 5 samples with multiple mutant alleles). In 5 of 5 cases with a single mutation, we observed a perfect match between the biopsy sample and the corresponding juice sample, with small differences apparent with respect to the proportion of the mutant alleles (Fig. 3) . In 3 of the 5 cases with a pancreatic juice sample showing multiple mutant alleles, analysis of the corresponding biopsy sample revealed only the presence of a single mutation. In the remaining 2 cases, multiple mutations were detected in the pancreatic juice and tissue samples. Whenever a mutation was determined to be present in the biopsy sample, it was always also present in the juice sample (Fig. 3) .
Discussion
The simultaneous quantification of distinct KRAS mutant alleles by means of digital PCR with the nanofluidic digital PCR array platform proved to be a robust and analytically sensitive method for both identifying and quantifying mutations in clinical samples. Not only were we able to assess the KRAS mutational load, we were also able to identify the presence of minor alleles consistently. This capability to detect and quantify dominant and minor alleles may provide new insights into the role of KRAS in colorectal and pancreatic disease.
Approximately 40% of colorectal carcinomas harbor KRAS mutations, mainly Asp and Val amino acid substitutions at codon 12. In our selected set of colorectal cancer biopsies partially enriched for KRAS mutant-positive cases, digital PCR analysis of the KRAS mutational load produced an 8% increase in the identification of KRAS mutant-positive tumors, compared with conventional PCR. Although this improvement is modest, it may represent a substantial contribution in selected clinical settings. The mutational load-the sum of frequencies of mutated alleles for a given case-in advanced adenomas and that in carcinomas are similar. Interestingly, there are apparent differences in allele distribution, however, in that minor alleles are detected more often in adenomas than in carcinomas. We interpret these findings as a reflection of the intrinsic heterogeneity of adenomas before their transformation, in contrast to carcinomas, in which clonal-selection processes are likely to occur. Of note is the fact that a large proportion of tumors are still KRAS mutation negative, demonstrating that the technique we have used is robust and not prone to produce falsepositive results.
Pancreatic juice has been shown to harbor multiple KRAS mutant alleles (34 ) . The usefulness of the digital PCR technique was also explored in pancreatic carcinomas in a completely distinct setting. Digital PCR scored the majority of pancreatic juice samples obtained from carcinomas of the exocrine pancreas as KRAS positive, thereby leading to reclassification of mutational status in up to 8 cases. That is a much higher number of added cases (20% of cases accurately reclassified), along with increased detection of multiple dominant or minor alleles.
The multiple mutated alleles detected reflect the intrinsic heterogeneity of the KRAS locus in pancreatic carcinoma, as is shown by the analysis of matched pancreatic juice and biopsy samples, where multiple alleles are often detected. Similar to the findings of a previous report (37 ) , heterogeneity is often higher in pancreatic juice than in the corresponding biopsy sample. In our small set of analyzed samples, minor alleles were found in biopsies in some cases and only in juice samples in others. DNA obtained from pancreatic juice permits extensive sampling of the pancreatic duct epithelium and might reflect a field effect in normal pancreatic tissue adjacent to the tumor or the presence of multiple lesions that could be well away from the resected neoplasm. Of note is that KRAS gene mutations appear to occur in a substantial proportion of intraductal lesions [pancreatic intraepithelial neoplasia (PanIN) 1a, 1b, 2, and 3 lesions (38 ) ], in 53% of adenomatous hyperplasias, and in 36% of papillary hyperplasias (39 )-all of which are precancerous conditions for pancreatic cancer. In other cases, however, this heterogeneity occurs within the tumor, suggesting the presence of a polyclonal growth even in advanced stages of the disease (15 ) .
In the clinical setting, the need exists to discriminate between chronic pancreatitis and carcinoma of the exocrine pancreas. In the small set of pancreatic masses occurring in chronic pancreatitis patients, KRAS mutations were identified in 2 of the masses. The presence of KRAS mutations has previously been reported in pancreatic juice samples obtained from patients with chronic pancreatitis (37, 40, 41 ) , a fact that has hampered the clinical usefulness of pancreatic juice. In a case in which a carcinoma was eventually diagnosed during follow-up, a dominant, highly prevalent mutant allele was detected. Thus, although the detection of a dominant allele may indicate a hidden carcinoma in some cases, the use of digital PCR does not overcome the limited analytical specificity of KRAS mutations for the diagnosis of pancreatic cancer.
We have shown that digital PCR is feasible with a commercially available platform. Our results show a consistently high analytical sensitivity, with no crossreactivity among the specific probes we used to detect distinct alleles. No clear standardized procedures for KRAS mutational testing have been established or proposed (20, 21 ) . The incremental clinical value offered by highly sensitive techniques needs to be established. Direct sequencing has an analytical sensitivity of approximately 20% for detecting single-base substitutions. Commercially available MALDI-TOF assays have an analytical sensitivity of 10%, whereas the ARMS (TheraScreen) assay is capable of detecting mu-tant alleles at frequencies as low as 1%. In some laboratories, such in-house techniques as mutant-enriched PCR (9 ) improves the prevalence and suggests better clinical performance. Our results indicate that the clinical relevance of highly sensitive techniques may differ, depending on the tumor and the clinical setting used.
Digital PCR offers a modest but definite increase in the detection of KRAS mutant-positive colorectal carcinomas, with no false positives. That may eventually produce a better tumor classification when genotyping is indicated prior to treatment with anti-epidermal growth factor receptor antibody. Finally, the costs of reagents per analyzed case are not high. We estimate that quantitatively detecting the 6 KRAS mutations in codon 12 costs approximately 125 euros per case in terms of the chip and reagents, a cost within the range of other marketed tests. The eventual addition of the codon 13 Asp mutant will be of interest. In colorectal tumors, we can anticipate a gain in KRAS mutationpositive tumors of at least 6%. The addition of 1 probe may cost 20 euros per sample. Next-generation sequencing techniques are making their way into the clinical setting. Key issues for a robust search for minor alleles are increased read depth and inherent noise (42 ) . In this continuously evolving scenario, the Fluidigm technology is a feasible alternative when assessing well-known hot spots.
On the other hand, the same methodology allows detection of multiple alleles, especially in distinct pancreatic samples. The proportion of pancreatic and ampullary samples harboring multiple mutant alleles is very high. Digital PCR has allowed the identification of multiple alleles in a substantial proportion of the analyzed samples. Although this finding is in line with previous observations (33, 36 -38, 43 ) , the clinical impact needs to be proved. In any case, the use of techniques of increased sensitivity provides new insights into the tumorigenesis process.
The translation of these findings to DNA obtained from paraffin blocks will be critical for expanding the technique's potential for use. In 3 of 4 cases, the profile of the DNA extracted from the paraffin block was similar to that obtained from high-quality DNA (data not shown). Our preliminary analysis suggests that dominant alleles are easily quantifiable but that minor alleles may be more difficult to detect. The performance of mutation-detection methods with DNA from routine formalin-fixed, paraffin-embedded tissue samples is variable. The continuous evolution in the methodologies available for DNA extraction from these stored tissues will be of help in improving the yield of the technique.
In conclusion, digital PCR provides a robust and quantitative measure of KRAS mutant alleles that can be used with routinely obtained samples. Our observations open the door to expand the concept of concomitant quantitative analysis of mutations to selected hot spots in other cancer genes. So far, using this methodology permits a better classification of tumors, with the potential clinical relevance depending on the tumor type analyzed. Future studies are indicated to evaluate the clinical utility of this methodology with respect to disease progression, the development of metastasis, choice of treatment, and early-detection strategies.
